Abstract
Antigen uptake and processing of exogenous proteins is critical for adaptive immunity, particularly for T helper cell activation. Proteins undergo distinct proteolytic processing in endolysosomal compartments of antigen-presenting cells. The resulting peptides are presented on MHC class II molecules and specifically recognized by T cells. The in vitro endolysosomal degradation assay mimics antigen processing by incubating a protein of interest with a protease cocktail derived from the endolysosomal compartments of antigen presenting cells. The kinetics of protein degradation is monitored by gel electrophoresis and allows calculation of a protein's half-life and thus endolysosomal stability. Processed peptides are analyzed by mass spectrometry and abundant peptide clusters are shown to harbor T cell epitopes. The endolysosomal degradation assay has been widely used to study allergens, which are IgE-binding proteins involved in type I hypersensitivity. In this review article, we provide the first comprehensive overview of the endolysosomal degradation of 29 isoallergens and variants originating from the PR-10, Ole e 1-like, pectate lyase, defensin polyproline-linked, non-specific lipid transfer, mite group 1, 2, and 5, and tropomyosin protein families. The assay method is described in detail and suggestions for improved standardization and reproducibility are provided. The current hypothesis implies that proteins with high endolysosomal stability can induce an efficient immune response, whereas highly unstable proteins are degraded early during antigen processing and therefore not efficient for MHC II peptide presentation. To validate this concept, systematic analyses of high and low allergenic representatives of protein families should be investigated. In addition to purified molecules, allergen extracts should be degraded to analyze potential matrix effects and gastrointestinal proteolysis of food allergens. In conclusion, individual protein susceptibility and peptides obtained from the endolysosomal degradation assay are powerful tools for understanding protein immunogenicity and T cell reactivity. Systematic studies and linkage with in vivo sensitization data will allow the establishment of (machine-learning) tools to aid prediction of immunogenicity and allergenicity. The orthogonal method could in the future be used for risk assessment of novel foods and in the generation of protein-based immunotherapeutics.
Introduction
Antigen processing of exogenous proteins plays a fundamental role in adaptive immunity particularly in T helper (Th) cell activation. Upon antigen uptake, proteins are proteolytically processed and cleaved within the endolysosomal compartments of antigen-presenting cells (APCs). The resulting antigen-specific peptides are loaded onto MHC class II and presented to Th cells. The peptides, specifically recognized by T cells, are called T cell epitopes, and detailed knowledge of these epitopes helps to understand fundamental steps in T cell immunity (). T cell epitopes can be determined experimentally by peptide mapping which requires antigen-specific human T cells and a large set of overlapping peptides sequences. Another method is in silico prediction which allow analysis of protein sequences (–), however these methods are limited to presentation on specific HLA types and always require experimental verification.
In 2005, the in vitro endolysosomal degradation assay was established to determine the susceptibility of proteins to endolysosomal proteases obtained from antigen-presenting cells (). This assay allows determination of a protein's half-life and later, a refined version of the assay also monitored proteolytic peptides containing potential T cell epitopes (). The endolysosomal degradation assay was mainly used for the analysis of IgE-binding molecules, which play a major role in type I hypersensitivity, affecting approximately 25%–30% of the population (). Knowledge on the susceptibility to endolysosomal degradation and T cell epitopes will support the development of novel allergy diagnostics and therapeutics. To date, studies have mainly focused on purified allergens while degradation studies on more complex mixtures or allergen extracts are not available. For a few purified allergens, systematic comparisons of endolysosomal degradation and immunogenicity were performed.
In this review, we provide a comprehensive overview of studies using in vitro processing of allergens by the endolysosomal degradation assay. So far, 29 allergenic molecules (including isoallergens and variants) from different protein families, i.e., Bet v 1, Ole e 1-like proteins, pectate lyases, defensin polyproline-linked proteins, non-specific lipid transfer proteins, mite group 1, 2, and 5 allergens, and tropomyosins have been investigated. Furthermore, the methodological part of the assay is discussed in detail and specific improvements for the next level of use are suggested. In addition to proteolytic susceptibility, protein-specific features such as thermal stability, tertiary fold and isoelectric point are considered for the first time. This could help in establishment of more general concepts linking endolysosomal degradation and immunogenicity of allergens.
Antigen processing of exogenous proteins and presentation on MHC II
Antigen-presenting cells (APCs) and antigen uptake
APCs sample the extracellular milieu and capture exogenous antigens. Dendritic cells (DCs), B cells, and macrophages are considered professional APCs with different functions during an immune response. DCs and B cells internalize antigens for presentation on MHC II, with DCs acting as initiators of an immune response as they survey the periphery to capture antigenic substances for transport to secondary lymphoid organs. Antigen presentation on B cells contributes to the humoral immune response, whereas macrophages are primarily involved in pathogen clearance (, ). DCs are the most important APCs due to their effective antigen capture and survival, high MHC II levels, adhesion and costimulatory molecules (, , ). Antigen uptake occurs via macropinocytosis or clathrin-mediated endocytosis. Macropinocytosis is fluid phase endocytosis mediated by membrane invagination to form a vessel with a large volume of extracellular fluid. In DCs, this process is constitutive and allows the uptake of large volumes of fluid, in contrast to growth factor-driven macropinocytosis in macrophages. Clathrin-mediated endocytosis provided by cell surface receptors represents specific uptake by receptors of the C-type lectin family such as mannose and transferrin receptors, as well as Fc receptors (, ).
Antigen processing by endolysosomal proteases
Internalized proteins are processed into peptides in multivesicular endolysosomal compartments. Proteins are initially translocated through vesicles referred to as early and late endosomes (). Maturation of endosomes from early to late stages involves luminal acidification of vesicles to provide an optimal low pH environment for resident proteases. Early endosomes have a pH milieu ranging from 5.9–6.8 and late endosomes from 4.9–6.0 (). Fusion of late endosomes with lysosomes is unidirectional and new hybrid organelles called endolysosomes are formed (). Lysosomal proteins and hydrolases are abundant in this compartment, where internalized proteins are efficiently degraded into peptides ().
Antigen presentation on MHC II
Due to high allelic polymorphisms and thus amino acid variations in the binding region, MHC can bind a wide range of processed peptides with high affinity. Peptides from endolysosomal degradation are transported on MHC II molecules and presented to CD4+T cells, while intracellular peptides obtained from proteasomal degradation are transported on MHC I and presented to CD8+T cells (). All nucleated cells express MHC I molecules, but only professional APCs constitutively express MHC II for surveillance of exogenous antigens (). MHC II molecules are assembled in the endoplasmic reticulum, and contain an invariant chain, that facilitates translocation to the endosomes and protects the peptide-binding groove. MHC II maturation is completed after processing the invariant chain into the class II-associated invariant chain peptide (CLIP). CLIP is then replaced by high-affinity peptides of optimal length of 18–20 residues obtained by progressive proteolysis in endolysosomes. The MHC II peptide complex is finally inserted into the cell membrane (, , ). Notably, antigen uptake enhances MHC II synthesis in the endolysosomes of immature DCs. In contrast, mature DCs typically exhibit high levels of peptide-loaded MHC II molecules on their cell surface ().
MHC II-bound peptides are recognized by CD4+T cells via T cell receptors. The first interaction between naïve T cells and MHC II peptide complexes occurs at secondary lymphoid organs and results in activation and clonal expansion of antigen-specific effector CD4+T cells or memory T cells. CD4+ T cells differentiate into Th2 subsets upon interaction with allergen-derived peptide-MHC II complexes combined with other interactions between the APC and T cell (e.g., CD40-CD40L, B7-CD28). Th2 cell differentiation is mainly driven by IL-4, low dose of antigen and low affinity between antigen and TCR (–). Consequently, Th2 cell differentiation also depends on protein stability during endolysosomal degradation, as optimal peptide abundance in late endosomes is a key factor for antigen presentation, T cell activation, and Th2 cell differentiation (). Differentiated Th2 cells secrete cytokines, mainly IL-4, IL-5 and IL-13, which contribute to IgE class switch as well as mast cell and eosinophil activation (, ).
Identification of T cell epitopes and simulated antigen processing methods
Processed peptides that are recognized by T cells and elicit an immune response are referred to as T cell epitopes. Peptides presented on MHC II are typically between 11 and more than 20 amino acids in length (). T cell epitopes can be identified by T cell activation assays using short overlapping synthetic peptides covering the entire protein sequence. T cell activation is evaluated by assessing cell proliferation, expression of activation markers, or the production of effector cytokines (). For T cell epitope mapping, peripheral blood mononuclear cells (PBMC) from allergic donors or allergen-specific T cell lines or clones were used. Using an array of synthetic overlapping peptides, stimulation indices of individual peptides reveal the allergen-specific T cell epitopes of allergens (, ). Another method to identify T cell epitopes is the elution of MHC II-bound peptides from APC and subsequent analysis by mass spectrometry (). A high-throughput platform for the analysis of MHC II peptide binding has been established for SARS-CoV-2 and may be extended to other diseases (). A comprehensive overview of identified T cell epitopes is provided by the Immune Epitope Database (www.iedb.org). In addition, in silico prediction tools can be used to reveal potential T cell epitopes (, ), which are however typically linked and thus restricted to individual human leukocyte antigens (HLAs).
Endolysosomal processing within APCs, including phagosomal activity, antigen degradation and presentation, can be measured by coupling labeled proteins to latex beads and monitoring intracellular and phagolysosomal degradation in a time-dependent manner by cytofluorometry. Ovalbumin, ß-lactoglobulin and peanut allergens have been studied using this intracellular degradation method (–). The results suggest a partial relationship between protein degradation and antigenicity, but further intracellular studies are required (). An alternative method is the endolysosomal degradation assay which is straightforward and additionally allows identification of proteolytic peptides. It mimics antigen processing by incubating proteins with endolysosomal proteases derived from APCs (). This assay does not require protein labeling or coupling but allows direct determination of proteolytic susceptibility and analysis of proteolytic peptides. This review focuses on endolysosomal degradation of allergens, which are IgE-binding proteins involved in allergic diseases that affect around 25%–30% of the population (, )
Antigen processing of allergens
Endolysosomal degradation assay
The endolysosomal degradation assay is an in vitro technique used to study the susceptibility of proteins to endolysosomal proteases (Figure 1). It was introduced by Delamarre et al. and further refined by Egger et al. to monitor allergen degradation (, ). The endolysosomal proteases are obtained from cultivated APCs. The mouse DC line JAWS II has been predominantly used for this purpose, but monocyte-derived DCs, bone marrow-derived DCs, B cells and macrophages have also been investigated (, , –). After culturing APCs, the cells are lysed in Tris/acetate pH 7.0 with sucrose and the microsomes are isolated by differential centrifugation. To isolate the protein content consisting of endolysosomal proteins including proteases, the microsomes are subjected to repeated freezing in liquid nitrogen and thawing at room temperature. The obtained microsomal content includes endolysosomal proteins and proteases. To simulate endolysosomal degradation, the (purified) protein of interest is incubated with the endolysosomal proteins in an acidic buffer. Most studies incubated 5 μg of protein with 7 or 7.5 μg of isolated microsomal proteins. Typically, the assay is performed in pH 4.8 citrate buffer containing the reducing agent dithiothreitol to mimic endolysosomal conditions. In addition, digests at pH 5.9, 5.2 and 4.5 have been used to simulate early and late endosomal proteolysis, respectively (, , –). The degradation of the protein of interest is monitored over time (up to 72 h) using reducing SDS-PAGE gel analysis. The susceptibility to proteases can be determined by densitometric measurement and calculation of the half-life of the protein (Figure 1). It is worth mentioning, that the simulated in vitro degradation process is considerably slower compared to in vivo processing. This is due to significantly lower protease concentrations (106-fold lower) used in the assay, which allows efficient protease usage and quantitative monitoring of the degradation (). In this way, half-lives of the allergens can be calculated and used for comparison.
Figure 1
The proteolytic peptides are further analyzed by mass spectrometry (MS) to identify peptide clusters. Peptide clusters are defined as part of the protein sequence in which several overlapping peptide fragments are identified during time-dependent degradation (Figure 1). These peptide clusters can identify potential peptide candidates for presentation on MHC molecules (T cell epitopes). The analysis of mass spectrometry data allows the investigation of experimentally determined T cell epitopes within the identified clusters (, , –). The endolysosomal degradation assay showed that the stability of proteins against endolysosomal proteases of APCs can be related to peptide processing and thus to the immune response (, , , ).
Different antigen presenting cells used for endolysosomal degradation of allergens
Originally, primary DCs from human (allergic) donors or mice were used to obtain endolysosomal proteases. Later, commercially available antigen presenting cell lines, such as the mouse cell line JAWS II were often used (Table 1). Compared to primary APCs, cell lines are an easily accessible and robust source, can be cultured in large quantities in a short time, and avoid the involvement of humans or animals. Comparison of human monocyte-derived DCs (mDCs), mouse bone marrow-derived DCs (BMDCs) and JAWS II showed that cathepsin A, B, C, D, L, S and Z, lysosomal prolylcarboxypeptidase and tripeptidyl peptidase 1 are present in all three DCs (, ). In terms of biological protease activity, similar half-lives of the major birch pollen allergen Bet v 1 were found after incubation with human and mouse primary DCs or the mouse cell line JAWS II and highly similar peptide clusters were generated. However, peptide appearance during the digestion and thus kinetics showed slight differences between the tested DCs. For example, after 36 h, peptides within the Bet v 1 residues1–22 were generated only by JAWS II, whereas the cluster at residue21–55 showed a slightly delayed appearance using human mDCs and JAWS II proteases (). These results overall indicate that proteases from different DCs irrespective of their source have similar proteolytic activities and peptide profiles thus supporting the use of cell lines for the endolysosomal degradation assay (Table 1).
Table 1
| Allergen characteristics | Endolysosomal degradation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergen molecule | Allergen source | Allergen tissue | Exposure route | Protein family/function | Mass of mature protein (kDa) | pI of mature protein | APCs used for isolation of endolysosomal enzymes | Buffer pH for digestion | Half-life (h) | References | |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | Human mDCs | 4.8 | 5 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | Human mDCs | 4.8 | 2 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | Mouse BMDCs | 4.8 | 2 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 2 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 7 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 5 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | A20 | 4.8 | >72 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | RAW 264.7 | 4.8 | 36 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | Activated RAW 264.7 | 4.8 | >72 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | Mouse BMDCs | 4.8 | 6 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 16 | () |
| rBet v 1.0101 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 14 | () |
| rBet v 1.0201 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.8 | Human mDCs | 4.8 | 4 | () |
| rBet v 1.0201 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.8 | Mouse BMDCs | 4.8 | 3 | () |
| rBet v 1.0201 | Birch | Betula verrucosa | Pollen | Inhalant | Bet v 1-like, PR-10 | 17 | 5.8 | JAWS II | 4.8 | 4 | () |
| rBet v 1.0101 codon harmonized | Birch | Betula verrucosa | Engineered | – | Bet v 1-like, PR-10 | 17 | 5.4 | JAWS II | 4.8 | 8 | () |
| rBM4 (hypoallergenic Bet v 1 fold variant) | Birch pollen | Betula verrucosa | Engineered | – | Bet v 1-like, PR-10 | 17 | 5.6 | Human mDCs | 4.8 | 0.5 | () |
| rBM4 (hypoallergenic Bet v 1 fold variant) | Birch pollen | Betula verrucosa | Engineered | – | Bet v 1-like, PR-10 | 17 | 5.6 | Mouse BMDCs | 4.8 | 9 | () |
| rOle e 1.0101 (A99 V, K106l, N111Q) | Olive | Olea europaea | Pollen | Inhalant | Ole e 1-like | 16 | 6.2 | JAWS II | 4.8 | 7 | () |
| rFra e 1.0101 | European ash | Fraxinus excelsior | Pollen | Inhalant | Ole e 1-like | 16 | 5.9 | JAWS II | 4.8 | 20 | () |
| rSal k 5.0101 (K3N, G84D, I91 V) | Prickly saltwort | Salsola kali | Pollen | Inhalant | Ole e 1-like | 16 | 5.0 | JAWS II | 4.8 | 55 | () |
| rChe a 1.0101 | Lamb's quarters, goosefoot | Chenopodium album | Pollen | Inhalant | Ole e 1-like | 18 | 4.9 | JAWS II | 4.8 | 65 | () |
| rPhl p 11.0101 (N24Q) | Timothy grass | Phleum pratense | Pollen | Inhalant | Ole e 1-like | 16 | 5.0 | JAWS II | 4.8 | 1 | () |
| rPla l 1.0101 | English plantain | Plantago lanceolata | Pollen | Inhalent | Ole e 1-like | 15 | 7.6 | JAWS II | 4.8 | >72 | () |
| rAmb a 1.0301 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.4 | JAWS II | 4.8 | 5 | () |
| rAmb a 1.0301 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.4 | A20 | 4.8 | 42 | () |
| rAmb a 1.0301 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.4 | RAW 264.7 | 4.8 | >72 | () |
| rAmb a 1.0301 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.4 | Activated RAW 264.7 | 4.8 | >72 | () |
| nAmb a 1.01 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.3 | JAWS II | 4.8 | 45 | () |
| nAmb a 1.01 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Pectate lyase | 40 | 5.3 | JAWS II | 4.5 | 12 | () |
| rArt v 1.0101 | Mugwort | Artemisia vulgaris | Pollen | Inhalant | Defensin-polyproline-linked protein | 11 | 8.2 | Human mDCs | 4.8 | 48–72 | () |
| rAmb a 4.0101 | Short ragweed | Ambrosia artemisiifolia | Pollen | Inhalant | Defensin-polyproline-linked protein | 14 | 4.9 | Human mDCs | 4.8 | 0.5–1 | () |
| rPar h 1.0101 | Santa Maria feverfew | Parthenium hysterophorus | Pollen | Inhalant | Defensin-polyproline-linked protein | 12 | 5.3 | Human mDCs | 4.8 | 1–3 | () |
| nPru p 3 | Peach | Prunus persica | Fruit | Ingested | nsLTP type 1 | 9 | 9.3 | Mouse BMDCs | 4.8 | 30 | () |
| nPru p 3 (reduced/alkylated) | Peach | Prunus persica | Engineered | – | nsLTP type 1 | 9 | 9.3 | Mouse BMDCs | 4.8 | 1 | () |
| rPru p 3.0102 | Peach | Prunus persica | Fruit | Ingested | nsLTP type 1 | 9 | 9.3 | Human mDCs | 4.8 | 32 | () |
| nPru 3.0102 | Peach | Prunus persica | Fruit | Ingested | nsLTP type 1 | 9 | 9.3 | Human mDCs | 4.8 | 27 | () |
| rCor a 8.0101 | Hazelnut | Corylus avellana | Tree nut | Ingested | nsLTP type 1 | 10 | 9.3 | Human mDCs | 4.8 | 12 | () |
| rArt v 3.0201 | Mugwort | Artemisia vulgaris | Pollen | Inhalant | nsLTP type 1 | 10 | 8.8 | Human mDCs | 4.8 | 11 | () |
| rApi g 2.0101 | Celery stalk | Apium graveolens | Vegetable | Ingested | nsLTP type 1 | 9 | 9.4 | Human mDCs | 4.8 | 18 | () |
| rApi g 6.0101 | Celery tuber | Apium graveolens | Vegetable | Ingested | nsLTP type 2 | 7 | 9.2 | Human mDCs | 4.8 | 17 | () |
| rPro-Der p 1.0102 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 1, cysteine protease | 34 | 5.5 | JAWS II | 4.8 | 42 | () |
| rPro-Der p 1.0102 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 1, cysteine protease | 34 | 5.5 | A20 | 4.8 | >72 | () |
| rPro-Der p 1.0102 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 1, cysteine protease | 34 | 5.5 | RAW 264.7 | 4.8 | 24 | () |
| rPro-Der p 1.0102 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 1, cysteine protease | 34 | 5.5 | Activated RAW 264.7 | 4.8 | 12 | () |
| rDer p 2.0103 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 2 allergen, MD-2 related | 14 | 7.1 | JAWS II | 4.8 | >72 | () |
| rDer p 2.0103 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 2 allergen, MD-2 related | 14 | 7.1 | A20 | 4.8 | >72 | () |
| rDer p 2.0103 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 2 allergen, MD-2 related | 14 | 7.1 | RAW 264.7 | 4.8 | >72 | () |
| rDer p 2.0103 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Mite group 2 allergen, MD-2 related | 14 | 7.1 | Activated RAW 264.7 | 4.8 | >72 | () |
| rBlo t 5.0101 | Tropical mite | Blomia tropicalis | Fecal pellets | Inhalant | Mite group 5 allergen | 14 | 5.3 | JAWS II | 4.8 | 4 | () |
| rBlo t 5.0101 short, N-terminal motif removed | Tropical mite | Blomia tropicalis | Fecal pellets | Inhalant | Mite group 5 allergen | 12 | 5.2 | JAWS II | 4.8 | 11 | () |
| rBlo t 5.0101 short, N-terminal motif removed | Tropical mite | Blomia tropicalis | Fecal pellets | Inhalant | Mite group 5 allergen | 12 | 5.2 | JAWS II | 4.8 | 9 | () |
| rBlo t 21.0101 short, N-terminal motif removed | Tropical mite | Blomia tropicalis | Fecal pellets | Inhalant | Mite group 21 allergen | 11 | 5.4 | JAWS II | 4.8 | 17 | () |
| rBTH1 (Blo t 5/21 hybrid WT sequence, N-terminal motif removed) | Tropical mite | Blomia tropicalis | Engineered | – | Hybrid mite group 5/21 allergen | 11 | 4.9 | JAWS II | 4.8 | 39 | () |
| rBTH2 (Blo t 5/21 hybrid, stability variant, N-terminal motif removed) | Tropical mite | Blomia tropicalis | Engineered | – | Hybrid mite group 5/21 allergen | 11 | 4.8 | JAWS II | 4.8 | 9 | () |
| rPen m 1.0101 | Black tiger shrimp | Penaeus monodon | Muscle tissue | Ingested | Tropomyosin | 33 | 4.7 | JAWS II | 5.2 | 24–48 | () |
| rPen m 1.0101 | Black tiger shrimp | Penaeus monodon | Muscle tissue | Ingested | Tropomyosin | 33 | 4.7 | JAWS II | 4.5 | 24–48 | () |
| rDer p 10.0101 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Tropomyosin | 33 | 4.8 | JAWS II | 5.2 | 12–24 | () |
| rDer p 10.0101 | European house dust mite | Dermatophagoides pteronyssinus | Fecal pellets | Inhalant | Tropomyosin | 33 | 4.8 | JAWS II | 4.5 | 24–48 | () |
| rBla g 7.0101 | German cockroach | Blattella germanica | Fecal pellets | Inhalant | Tropomyosin | 33 | 4.7 | JAWS II | 5.2 | 12–24 | () |
| rBla g 7.0101 | German cockroach | Blattella germanica | Fecal pellets | Inhalant | Tropomyosin | 33 | 4.7 | JAWS II | 4.5 | 12–24 | () |
| rAni s 3.0101 | Herring worm larvae | Anisakis simplex | Fish muscle tissue | Ingested | Tropomyosin | 33 | 4.7 | JAWS II | 5.2 | 8–12 | () |
| rAni s 3.0101 | Herring worm larvae | Anisakis simplex | Fish muscle tissue | Ingested | Tropomyosin | 33 | 4.7 | JAWS II | 4.5 | 12–24 | () |
Characteristics and half-lives of allergens analyzed by the endolysosomal degradation assay.
Allergen designations according to WHO/IUIS Allergen Nomenclature Sub-committee. Half-lives in italic represent estimated half-lives obtained with densitometric analyses using protein gel electrophoresis data provided in the original publications. Recombinant allergens were obtained from E. coli, except for Ole e 1, Fra e 1, Sal k 5, Che a 1 and Phl p 11 which were produced in P. pastoris.
r, recombinant; n, natural; nsLTP, non-specific lipid transfer protein; PR, pathogenesis-related.
The activity of endolysosomal degradation is regulated according to the biological function of the APCs. Compared to DCs and B cells, macrophages present higher levels of proteases, resulting in enhanced degradation of casein and ovalbumin (). Specifically, the activity of cysteine proteases determined by a peptide-based assay in murine cell lines was shown to be 6.3-fold higher in endolysosomes of RAW 264.7 macrophages but 151-fold lower in A20 B cells compared to JAWS II (). Thus, the amount of endolysosomal proteins in the degradation assay of this study was adjusted, but not fully equivalent, as shown by the different degradation kinetics of Bet v 1 (Table 1). Standardization on the activity of the entire protease panel is required for efficient comparison of endolysosomal proteases from different antigen-presenting cells and studies performed in different laboratories. Among endolysosomal proteases, cathepsins are the most abundant protease family (). For example, digestion of Bet v 1 with purified cathepsin S generated 8 out of 13 endolysosomal peptide clusters, demonstrating the involvement of cathepsin S in early protein processing (). Ole e 1, the major olive pollen allergen is typically completely digested within 8 h, while this process was considerably delayed to more than 36 h when a cathepsin S inhibitor was used. Cathepsin S-inhibited degradation showed similar peptide clusters, albeit with limited peptide diversity and up to 28-fold reduction in the total peptide amounts ().
Proteolytic stability, endolysosomal peptide clusters and antigenicity of allergenic proteins
In this chapter, detailed information on the endolysosomal stability of 29 allergens from ten protein families obtained from the literature is provided (Table 1). The stability of each protein is expressed as half-life, defined as timepoint when 50% is digested. If the half-life was not provided in the studies, we determined the values by densitometric analyses using protein gel electrophoresis data retrieved from the original papers. Purified allergens were obtained from natural sources or produced in E. coli, except for Ole e 1, Fra e 1, Sal k 5, Che a 1 and Phl p 11 which were produced in P. pastoris. These allergens were digested with proteases obtained from the endolysosomal compartments of mainly DCs and in some cases from B cells and macrophages. No obvious association between endolysosomal half-life and allergenic sensitization capacity is detectable and major differences within protein families are noted (Figure 2). However, allergens of minor sensitization prevalence typically showed very low half-lives, while the majority with medium half-lives are considered moderate to strong allergenic sensitizers. While the endolysosomal stability is generally relevant for immunogenicity, further intrinsic or context-related factors seem to further influence the development of a Th2 response and allergy.
Figure 2
From the literature, we additionally collected information on peptide clusters identified by mass spectrometry. These clusters are typically longer than the presented T cell epitopes, as peptides are additionally trimmed. However, these clusters provide an important overview of the relevant peptides and the kinetics of their appearance. To allow comparison between different studies, the numbering of T cell epitopes and identified clusters is provided considering the mature proteins without signal peptides, unless otherwise stated. Finally, the antigenic potential of the investigated proteins is discussed when immunization data were available.
Bet v 1-like, pathogenesis-related 10 proteins
Bet v 1 is the major allergen of birch pollen with a sensitization frequency of 95% and belongs to the plant pathogenesis related-10 (PR-10) protein family (). Twenty-seven isoallergens have been identified to date, with Bet v 1 isoforms and fold variants being the most studied molecules with respect to endolysosomal degradation (, ). Studies with endolysosomal proteases from DCs showed half-lives of Bet v 1.0101 ranging from 1.8 to 14 h (, , ). The first studies showed comparatively shorter half-lives of 2 and 5 h (, ), while further work typically suggested longer periods of time. The observed discrepancies for the half-lives of Bet v 1.0101 might relate to different protein quantification methods used for determining protein concentrations of the isolated protein as well as for the endolysosomal fraction and/or differences in protease activity in the endolysosomal protein cocktail. During simulated endolysosomal degradation of allergens, the degradation buffer of the assay is typically maintained at pH 4.8 (, ). To specifically address the pH difference in the antigen processing compartments, a study on kinetics and peptide clusters of Bet v 1 was performed with pH conditions of 5.9, 5.2, and 4.5, simulating early to late endosomal compartments (). Degradation of Bet v 1 with JAWS II endolysosomal proteases demonstrated that the allergen was degraded significantly faster at lower pH, while at pH 5.9 intact protein was still present after 48 h. Furthermore, Bet v 1 was completely degraded at pH 5.2 after 24 h and at pH 4.5 already after 6 h ().
Recombinant Bet v 1.0101 and E. coli DNA codon-harmonized Bet v 1.0101 were compared regarding structural and immunological aspects (). Regarding endolysosomal degradation, similar half-lives of 7 and 8 h were observed for Bet v 1.0101 and the codon-harmonized protein, respectively. Both proteins also showed comparable IgE binding capacities suggesting equivalent 3-dimensional structures. To alter the immunomodulatory properties of Bet v 1 by ligand binding, retinoic acid bound Bet v 1.0101 was investigated. Using JAWS II cells, the endolysosomal degradation kinetics of Bet v 1.0101 remained the same when retinoic acid was bound to the allergen, although allergenicity was shown to be reduced (). On the other hand, coupling of Bet v 1.0101 to SiO2 nanoparticles resulted in significantly lower stability during endolysosomal degradation with JAWS II proteases (). The estimated half-life was strongly reduced from 14 h to only 1 h. The difference suggests that conjugation with SiO2 nanoparticles resulted in conformational changes of Bet v 1.0101 leading to increased exposure of proteolytic cleavage sites. At the same time, IgE and T cell reactivity were similar but SiO2 conjugated Bet v 1.010 showed a more pronounced Th1 profile ().
Isoform Bet v 1.0201 (previously known as Bet v 1.0401 or Bet v 1d) is considered a naturally occurring hypoallergen based on lower IgE binding and retained T cell activation compared to Bet v 1.0101 (, ). Endolysosomal degradation with proteases isolated from mouse BMDC, human mDC and JAWS II showed that Bet v 1.0201 is more resistant to proteolysis (half-lives 3.9–4.1 h) compared to Bet v 1.0101 (half-lives 1.8–2.1 h) (). In another study, Bet v 1.0201 also showed slightly increased stability to endolysosomal degradation compared to Bet v 1.0101 (). Mice immunized with Bet v 1.0201 showed similar IgE responses, whereas higher IgG and IgA levels were observed consistent with enhanced antigen uptake of isoform 1.0201 (). Based on in silico calculations, local unfolding of Bet v 1.0201 provides more accessible cleavage sites, which would argue for increased proteolytic susceptibility (, ). In contrast to Bet v 1.0101, Bet v 1.0201 exists as cysteine-mediated dimer which might explain the difference between theoretical and observed accessibility to proteolysis.
An engineered fold variant of Bet v 1 (BM4) incorporating 7 consecutive amino acids from the homologous apple allergen Mal d 1 showed a loss of the typical PR-10 fold (). Endolysosomal degradation of BM4 with mouse BMDC-derived proteases resulted in a half-life of 9 h (complete degradation at 24 h) compared to 6 h (complete degradation after 12 h) for Bet v 1.0101. In another study, BM4 proved to be more susceptible to endolysosomal degradation with a half-life of approximately 0.5 compared to 2 h for Bet v 1.0101 (). In addition, BM4 was taken up more efficiently by human PBMCs and thus faster intracellular degradation was observed supporting the lower resistance to endolysosomal degradation (). This observed discrepancy in stability might be attributed to the fact that proteases in the two different studies were obtained from mouse BMCDs and human mDCs. In addition, variations in batches and determination of protein concentrations would influence proteolysis, which is however beyond identifiable data.
Immunogenicity testing of BM4 with PBMCs from birch pollen allergic patients and Bet v 1-specific T cell clones showed higher T cell proliferation compared to Bet v 1.0101 (, ). Immunization of mice with BM4 triggered higher levels of Bet v 1-specific IgG1 and IgG2a and IgE compared to Bet v 1.0101. While cytokine profiles indicated a Th2 polarization using Bet v 1.0101, immunization with BM4 resulted in a mixed Th1/Th2 response. As mentioned above, two different patterns were observed showing both higher and lower susceptibility of BM4 compared to Bet v 1.0101 to endolysosomal degradation. It was suggested that higher endolysosomal stability of BM4 led to the observed shift towards a Th1 immune response. On the other hand, higher susceptibility was attributed to increased access to proteolytic sites in the fold variant BM4 (, ).
Proteolytic cleavage sites of Bet v 1 are mostly located within inaccessible secondary structural elements, thus local unfolding is required to expose proteolytic sites. For that reason, structural stability and unfolding ability are thought to be intrinsically linked to protein degradation (). To test this hypothesis, four fold-stabilized variants of Bet v 1.0101 designated Bet_mut1 (D69I), Bet_mut2 (D69I, K97I), Bet_mut3 (D69I, K97I, P90l), Bet_mut4 (D69I, K97I, P90l, G26l), were generated with similar three-dimensional structure but strongly enhanced thermal and chemical stability (). In the endolysosomal degradation assay, wild-type Bet v 1 and variants were digested at different acidic conditions (pH 5.9, 5.2, and 4.5) (Figure 3). All proteins remained intact when digested at pH 5.9, which mimics the early endosomes milieu. Bet v 1.0101 showed higher susceptibility to proteolysis at pH 5.2 (half-life 7 h) and pH 4.5 (half-life 0.5 h) compared to all fold-stabilized variants which (expect for Bet_mut4) showed significantly higher endolysosomal stability (Table 1). Bet_mut4 was only efficiently degraded at pH 4.5 (half-life 10 h). The endolysosomal degradation results are consistent with the thermal and chemical stability of the molecules.
Figure 3
The immunogenicity of the proteins was tested by intradermal administration in BALB/c mice (
Peptide clusters generated by endolysosomal degradation of Bet v 1.0101 are typically located around residues 1-22, 83-115 and, to a lesser extent around 146-159. They all contain the previously identified T cell epitopes, i.e., Bet v 14−18, Bet v 182−96, and Bet v 1142−156. In addition to the regions containing T cell epitopes, there was also a strong peptide cluster located at 36-55 (
Endolysosomal degradation of the Bet v 1.0201 isoform with DC proteases produced peptide clusters similar to those of Bet v 1.0101. However, in accordance with the higher endolysosomal stability, cluster formation was slightly delayed (
Information on endolysosomal degradation of other Bet v 1-like allergens from food sources was also found. Variants of the major allergenic apple and hazelnut PR-10 proteins Mal d 1.0108 and Cor a 1.0401 were generated to compare immunogenicity, allergenicity and proteolytic susceptibility with the respective wild-type allergens (
Endolysosomal peptide clusters of Mal d 1.0108 and Api g 1.0101 obtained by degradation with moDCs were located within residues 1–22, 23–36, 83–102, 146–157 (early appearing peptides) followed by 33–55, 56–65, and 103–115 (late appearing peptides). The same localization of peptides clusters were previously also identified in Bet v 1.0101 digestions (
Ole e 1—like proteins
The Ole e 1-like protein family includes 15 pollen-derived allergens, the biological function of which is still unknown. The prototypic member Ole e 1 is the major allergen of olive pollen which causes seasonal allergic reactions predominately in the Mediterranean area (
T cell epitope mapping studies with Ole e 1 revealed immunodominant epitopes at residues 91–102, 109–120, and 119–130 (
Three in silico predicted Fra e 1 peptides were tested using human PBMCs and confirmed 21–35, 35–45 and 121–135 as T cell epitopes (
Phl p 11 presents one experimentally verified T cell epitope at residues 111–125. However, the number of peptides tested was small and ultimately validated in only one patient (
For Sal k 5 and Che a 1, data are limited to in silico prediction of T cell epitopes. Both allergens show several peptide clusters containing partially predicted epitopes after endolysosomal degradation. However, some in silico predicted epitopes included dominant proteolytic cleavage sites in the degradation assay. Using the endolysosomal degradation assay, six allergenic Ole e 1-like proteins were analyzed (
Pectate lyases
Amb a 1, a member of the pectate lyase C family, is the major allergen of short ragweed, accounting for 90% of sensitization and 50% of IgE reactivity in ragweed pollen (
Amb a 1 epitope mapping studies revealed dominant T cell epitopes at Amb a 1 residues 178–189, 199–216, 280–295, 304–319, 320–335, 343–357, and 361–394 (
Non-specific lipid transfer proteins
Non-specific lipid transfer proteins (nsLTPs) are relevant primary food allergens in southern Europe and parts of Asia (
Pru p 3 is the major peach allergen and the prototypical allergen of the nsLTP1 family (
Celery can cause allergic reactions ranging from mild oral allergy syndromes to severe anaphylactic reactions associated with highly stable allergens (
Art v 3 is a relevant allergenic nsLTP1 from mugwort pollen. Endolysosomal degradation with mDC of nsLTP allergic donors showed a half-life of 11 h (
Plant defensins
Defensins are ubiquitous plant peptides that play a role in pathogen defense (PR-12 family). They possess a disulfide bond stabilized structure that provides high resistance to extreme pH, temperature and protease degradation. Allergenic defensins from pollen additionally contain a C-terminally linked polyproline domain designated defensin polyproline-linked protein (DPLP). Particularly Art v 1 from mugwort pollen shows cross-reactivity with food defensins, which can lead to pollen food syndromes (
Endolysosomal degradation of Art v 1, Amb a 4 and Par h 1 revealed similar peptide clusters within the analyzed defensin-like domain. For all three allergens, a large peptide cluster spanning residues 25–43 was observed (
Mite group 1 and 2 allergens
Der p 1 and Der p 2 are two major house dust mite allergens found in the fecal pellets and account for >80% of IgE reactivity in house dust mite allergic individuals (92). Endolysosomal degradation of recombinant pro-Der p 1 (Der p 1.0102 including the N-terminal pro-peptide) with proteases from JAWS II and A20 revealed high proteolytic resistance with half-lives of 42 and >72 h, respectively. The use of inactive and activated macrophages (RAW 264.7) resulted in half-lives of 21 and 12 h, respectively. Besides the generally low amount of endolysosomal peptides as a consequence of the high protein stability, the most prominent clusters were interestingly observed in the Der p 1 pro-peptide, i.e., residues 41–51 and 52–62 (
Der p 2 showed very high resistance to endolysosomal degradation with proteases from JAWS II, A20 and RAW 264.7 cells. Since most of the allergen was still intact after 72 h, calculation of the half-lives was not possible and remains to be determined (
Mite group 5 and group 21 allergens
Blo t 5 is a major allergen of tropical mites, found in the gut and feces, with >70% IgE reactivity in allergic individuals (98). Degradation of recombinant Blo t 5 with JAWS II proteases revealed a high susceptibility and no detectable intact protein after 6 h. An N-terminally truncated allergen lacking the 1-18 residue disordered motif (referred to as Blo t 5-short), corresponding to the processed protein found in nature, was more stable and showed increased resistance to endolysosomal degradation (intact protein up to 24 h) (
Blo t 21 is another major allergen found in the gut and feces of tropical mites. It shares 39% sequence identity with Blo t 5 and co-sensitization is often observed (101, 102). Degradation of Blo t 21-short (deletion of the N-terminally disordered motif) with proteases from JAWS II endolysosomes revealed a half-life of ∼17 h, which is higher compared to Blo t 5 (∼9 h). Two prominent peptide clusters between amino acids 35-52 and 92-113 were observed throughout the digestion period of 48 h, although the number of peptides in the C-terminal cluster decreased with time. Experimentally identified T cell epitopes of Blo t 21 are not yet available. However, in silico prediction suggests a large T cell epitope between residues 92–103, which is within the peptide cluster found by endolysosomal degradation (
In addition, two hybrid molecules of Blo t 5 and 21 were generated by fusing identified T cell epitopes and excluding the disordered N-terminal motif. BTH1 represents the wild-type sequence, while BTH2 is a hybrid molecule with point mutations for improved protein stability and hypoallergenicity. While no increased thermal stability of BTH2 was observed, this hybrid showed lower IgE binding reactivity compared to Blo t 5 and Blo t 21 as well as the hybrid BTH1. When the hybrids were tested for susceptibility to JAWS II endolysosomal proteases, the half-lives were 39 h for BTH1 and 9 h for BTH2. These results are consistent with the general protein stability measured during thermal denaturation (BTH1 Tm = 64°C, BTH2 Tm = 52°C). With respect to thermal and endolysosomal stability, BTH1 was enhanced while BTH2 was slightly decreased compared to the wild-type allergens (Blo t 5 Tm = 56°C, Blo t 21 Tm = 57°C). BTH2 was immunogenic and induced a shift towards a Th1 response in mice. A comparison of immunogenicity and antigenicity with the wild-type allergens and BTH1 was not possible as these were not evaluated in the mouse model. During endolysosomal degradation, both BTH1 and BTH2 showed peptide clusters at residues 1–17, 19–42, 47–61 and 72–90 (numbering including the N-terminal disordered motif corresponds to residues 18–34, 36–59, 64–78, 89–107). The experimental mouse T cell epitope of Blo t 5 was not represented in the identified peptide clusters. However, BTH2 in particular generated many C-terminal peptides that are consistent with a predicted Blo t 21 T cell epitope, but those require further investigation (
Tropomysosins
Tropomyosins from four different species were studied using the endolysosomal degradation assay with proteases from JAWS II cells (
Bla g 7 is a minor cockroach allergen with a sensitization rate of 16% in cockroach allergic patients (105). Degradation of Bla g 7 resulted in progressive proteolysis, but the intact allergen was still detectable after 48 h of degradation and, similar to Pen m 1, stable intermediate protein fragments of 35–38 kDa were observed. Ani s 3 is the tropomyosin of the parasitic herring worm larvae, and high IgE levels due to cross-reactivity can be observed in sensitized patients (106). Endolysosomal degradation of Ani s 3 resulted in complete degradation after 48 h at pH 5.2, while it was still detectable when digested at pH 4.5. Similar to Der p 10, a stable protein intermediate of 38 kDa was observed. Except for Ani s 3, the tropomyosins showed similar stability during thermal processing under neutral or acidic conditions. While Ani s 3 is heat-labile at neutral pH, it gains stability under acidic conditions (pH 5.2). Interestingly, protein stability during endolysosomal degradation appeared to be higher at pH 4.5, in contrast to the observations made with Bet v 1 and variants. Tropomyosins are generally very stable in acidic environments and for optimal comparison (107), proteins that are class 1 food allergens and could sensitize via the gastrointestinal tract should be pre-treated using gastric and intestinal enzymes before endolysosomal digestion.
Consistent with the higher stability of all tropomyosins at pH 4.5 as observed by gel electrophoresis, only a few peptides, mostly localized to the N-terminus of the proteins, were detectable after 24 h of digestion. This confirms that a lower pH stabilizes the studied tropomyosins, leaving more intact protein or stable intermediate large protein fragments and thus producing fewer peptide fragments (
Endolysosomal degradation of Der p 10 at pH 5.2 resulted in peptide clusters at 14–30, 31–45 and 80–90, while at pH 4.5 a cluster at 12–35 was observed. Degradation of Bla g 7 resulted in peptide clusters at 1–10, 10–25, 30–45, 70–90, 95–105, 115–130, 130–150, 155–170, 170–200. At pH 4.5, a peptide cluster was detected at 10–25. Degradation of Ani s 3 at pH 5.2 produced many peptide clusters spanning almost the entire sequence. Specifically, peptides were aligned at residues 1–10, 10–30, 50–80, 110–130, 135–150, 150–170, 170–200, 205–230, 250–270. Interestingly, Ani s 3 showed a different profile with more peptide clusters generated in the middle and C-terminus of the protein (
Conclusions
The endolysosomal degradation assay is a powerful in vitro tool to mimic proteolytic processing in the endolysosomal compartment. The straightforward assay allows the determination of endolysosomal stability which is expressed as half-life of a protein under distinct methodological settings. Identified peptide clusters can be considered as T cell epitope candidates and thus, in combination with in silico MHC II binding studies, narrow down the number of synthetic peptides to be tested in T cell epitope mapping studies. This would be particularly relevant in allergy research as experimentally verified T cell epitopes are not available for all IgE-binding molecules. In addition, the time-dependent appearance of peptide clusters can be analyzed, providing additional data for predicting protein stability and cleavage accessibility to proteases (
A limitation of the endolysosomal degradation assay seems to be the moderate reproducibility of protein degradation kinetics and thus protein stability. For example, the determined half-lives of Bet v 1.0101 ranged from 2 to 14 h, which allows only comparisons of proteins within the same experiment. The source of the observed divergences could be related to different levels of proteolytic enzymes in the analyzed antigen-presenting cells and/or different activity of the endolysosomal protein cocktail. In addition, the protocols are not fully harmonized regarding the ratio of allergen to proteolytic enzymes (5 µg of allergen is digested with 7 or 7.5 µg of proteins from the endolysosomal compartment). Different methods (e.g., colorimetric vs. UV-based methods or amino acid analysis) used for protein quantification could also influence the endolysosomal degradation, which in turn influences the ratio of digestible protein to proteases. The different degradation susceptibility when digested at different pH conditions also indicates the importance of correct buffer settings when performing the assay.
Peptide clusters identified by mass spectrometry-based analysis have traditionally considered the identification of different peptides within a given protein region. This can lead to both over- and under-estimation of clusters, as many slightly different peptides are considered more relevant in graphical representations. In general, there is a need for additional standardization of endolysosomal degradation to allow for assay and laboratory independent comparison of different proteins.
To improve the reproducibility of the assay and to link it to immunogenicity, a standardized endolysosomal degradation assay is being developed within the EU-funded project Allergenicity Prediction Toolbox for Novel Foods (ALLPreT). One of the key points is the a priori determination of the proteolytic activity of the endolysosomal cocktail by quantitative digestion of reference proteins (e.g., casein) and/or peptides (e.g., cathepsin substrates). We also plan to validate appropriate protein concentration measurements, determination of half-lives and quantitative peptide readout considering peptide intensities. Within ALLPreT, the endolysosomal degradation of allergens as well as non-allergenic homologues from legumes will be analyzed and linked to immunogenicity data from animal studies and human IgE sensitization. In addition, the influence of the food matrix, heating of the proteins and gastrointestinal pre-digestion will be considered for the first time. In addition to professional antigen-presenting cells, other cells such as neutrophils can become functional APCs (111, 112). Epithelial cells and their endolysosomal proteases are of particular interest as these cells are relevant for allergic sensitization and can act as antigen presenting cells (113, 114). Therefore, ALLPreT aims to compare different antigen presenting cells with respect to their endolysosomal degradation potency, proteolytic content, and activity.
As a general hypothesis, proteins that show moderate to high stability during endolysosomal proteolysis can efficiently induce an immune response. In contrast, unstable proteins that are degraded early and completely within the endolysosomal compartment lack peptides for presentation and thus show low immunogenicity (
The extent of T cell receptor interaction with peptide MHC II complexes influences the differentiation fate of naïve T cells (
Currently, in vitro endolysosomal studies investigating different pH conditions of allergens are limited to three studies. Machado et al. proposed a mechanism for antigen presentation of Bet v 1 that seems to be most efficient when the antigen is stable in the early endosome (higher pH) followed by sufficient degradation in the late endosome (lower pH) (
In conclusion, the susceptibility and peptides obtained from the endolysosomal degradation assay are powerful tools for understanding protein immunogenicity and T cell reactivity. Systematic analysis and linkage with physicochemical as well as immunological data will enable the establishment of generally applicable tools for use in machine learning that could be useful for predicting protein immunogenicity and allergenicity. This feature could in the future be used for risk assessment of novel foods and in the generation of protein-based immunotherapeutics.
Statements
Author contributions
EÖ: Conceptualization, Formal Analysis, Visualization, Writing – original draft, Writing – review & editing, Data curation, Methodology. GG: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing, Investigation, Resources.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
The ALLPreT project has received funding from the European Union’s Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101072377. Open access publication was supported by the Paris Lodron University of Salzburg Publication Fund. The funding bodies had no role in planning or writing of the review article.
Acknowledgments
We thank Kitty Verhoeckx for valuable input on the topic and the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
BlumJSWearschPACresswellP. Pathways of antigen processing. Annu Rev Immunol. (2013) 31:443–73. 10.1146/annurev-immunol-032712-095910
2.
YangYWeiZCiaGSongXPucciFRoomanMet alMHCII-peptide presentation: an assessment of the state-of-the-art prediction methods. Front Immunol. (2024) 15:1293706. 10.3389/fimmu.2024.1293706
3.
Schaap-JohansenA-LVujovićMBorchAHadrupSRMarcatiliP. T cell epitope prediction and its application to immunotherapy. Front Immunol. (2021) 12. 10.3389/fimmu.2021.712488
4.
Sanchez-TrincadoJLGomez-PerosanzMRechePA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. (2017) 2017(1):2680160. 10.1155/2017/2680160
5.
DelamarreLPackMChangHMellmanITrombettaES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. (2005) 307(5715):1630–4. 10.1126/science.1108003
6.
EggerMJuretsAWallnerMBrizaPRuzekSHainzlSet alAssessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome. PLoS One. (2011) 6(2):e17278. 10.1371/journal.pone.0017278
7.
DramburgSHilgerCSantosAFde las VecillasLAalberseRCAcevedoNet alEAACI molecular allergology user’s guide 2.0. Pediatr Allergy Immunol. (2023) 34(S28):e13854. 10.1111/pai.13854
8.
RastogiIJeonDMosemanJEMuralidharAPotluriHKMcNeelDG. Role of B cells as antigen presenting cells. Front Immunol. (2022) 13:954936. 10.3389/fimmu.2022.954936
9.
LiuK. Dendritic cells. In: BradshawRAStahlPD, editors. Encyclopedia of Cell Biology. Waltham: Academic Press (2016). p. 741–9.
10.
LanzavecchiaA. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. (1996) 8(3):348–54. 10.1016/S0952-7915(96)80124-5
11.
HumeniukPDubielaPHoffmann-SommergruberK. Dendritic cells and their role in allergy: uptake, proteolytic processing and presentation of allergens. Int J Mol Sci. (2017) 18(7):1491. 10.3390/ijms18071491
12.
MaxfieldFRYamashiroDJ. Endosome acidification and the pathways of receptor-mediated endocytosis. Adv Exp Med Biol. (1987) 225:189–98. 10.1007/978-1-4684-5442-0_16
13.
HuotariJHeleniusA. Endosome maturation. EMBO J. (2011) 30(17):3481–500. 10.1038/emboj.2011.286
14.
DuclosSClavarinoGRousserieGGoyetteGBoulaisJCamossettoVet alThe endosomal proteome of macrophage and dendritic cells. Proteomics. (2011) 11(5):854–64. 10.1002/pmic.201000577
15.
RochePAFurutaK. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. (2015) 15(4):203–16. 10.1038/nri3818
16.
O'BrienCFlowerDRFeigheryC. Peptide length significantly influences in vitro affinity for MHC class II molecules. Immunome Res. (2008) 4:6. 10.1186/1745-7580-4-6
17.
van PanhuysNKlauschenFGermain RonaldN. T-cell-receptor-dependent signal intensity dominantly controls CD4+ T cell polarization in vivo. Immunity. (2014) 41(1):63–74. 10.1016/j.immuni.2014.06.003
18.
HoskenNAShibuyaKHeathAWMurphyKMO'GarraA. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med. (1995) 182(5):1579–84. 10.1084/jem.182.5.1579
19.
ScheiblhoferSLaimerJMachadoYWeissRThalhamerJ. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev Vaccines. (2017) 16(5):479–89. 10.1080/14760584.2017.1306441
20.
MilnerJDFazilleauNMcHeyzer-WilliamsMPaulW. Cutting edge: lack of high affinity competition for peptide in polyclonal CD4+ responses unmasks IL-4 production. J Immunol. (2010) 184(12):6569–73. 10.4049/jimmunol.1000674
21.
HwangJRByeonYKimDParkSG. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp Mol Med. (2020) 52(5):750–61. 10.1038/s12276-020-0435-8
22.
ChoppLRedmondCO’SheaJJSchwartzDM. From thymus to tissues and tumors: a review of T-cell biology. J Allergy Clin Immunol. (2023) 151(1):81–97. 10.1016/j.jaci.2022.10.011
23.
RosaDSRibeiroSPCunha-NetoE. CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp. (2010) 58(2):121–30. 10.1007/s00005-010-0067-0
24.
ZappasodiRBudhuSAbu-AkeelMMerghoubT. In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods Enzymol. (2020) 631:43–59. 10.1016/bs.mie.2019.08.012
25.
HoferHAsamCHauserMNaglBLaimerJHimlyMet alTackling bet v 1 and associated food allergies with a single hybrid protein. J Allergy Clin Immunol. (2017) 140(2):525–33.e10. 10.1016/j.jaci.2016.09.055
26.
Jahn-SchmidBKelemenPHimlyMBohleBFischerGFerreiraFet alThe T cell response to art v 1, the major mugwort pollen allergen, is dominated by one Epitope1. J Immunol. (2002) 169(10):6005–11. 10.4049/jimmunol.169.10.6005
27.
MutschlechnerSEggerMBrizaPWallnerMLacknerPKarleAet alNaturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol. (2010) 125(3):711–8. 8e1–8e2. 10.1016/j.jaci.2009.10.052
28.
ObermairFJRenouxFHeerSLeeCHCereghettiNLoiMet alHigh-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4T cell targets and mechanisms of immune escape. Sci Adv. (2022) 8(17):eabl5394. 10.1126/sciadv.abl5394
29.
HoffmannEKotsiasFVisentinGBruhnsPSavinaAAmigorenaS. Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proc Natl Acad Sci U S A. (2012) 109(36):14556–61. 10.1073/pnas.1203912109
30.
SavinaAVargasPGuermonprezPLennonAMAmigorenaS. Measuring pH, ROS production, maturation, and degradation in dendritic cell phagosomes using cytofluorometry-based assays. Methods Mol Biol. (2010) 595:383–402. 10.1007/978-1-60761-421-0_25
31.
SmitJJSonnetFPietersR. Receptor Mediated Uptake of Peanut Proteins in Dendritic Cells. EAACI; 17–21 June 2017. Helsinki, Finland: John Wiley and Sons Ltd (2017). p. 315.
32.
ChanSKPomesAHilgerCDaviesJMMuellerGKuehnAet alKeeping allergen names clear and defined. Front Immunol. (2019) 10:2600. 10.3389/fimmu.2019.02600
33.
MachadoYFreierRScheiblhoferSThalhamerTMayrMBrizaPet alFold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen. J Allergy Clin Immunol. (2016) 137(5):1525–34. 10.1016/j.jaci.2015.09.026
34.
WildnerSElsasserBStemesederTBrizaPSohWTVillalbaMet alEndolysosomal degradation of allergenic ole e 1-like proteins: analysis of proteolytic cleavage sites revealing T cell epitope-containing peptides. Int J Mol Sci. (2017) 18(8):1780. 10.3390/ijms18081780
35.
HoferHWeidingerTBrizaPAsamCWolfMTwarochTet alComparing proteolytic fingerprints of antigen-presenting cells during allergen processing. Int J Mol Sci. (2017) 18(6):1225. 10.3390/ijms18061225
36.
WolfMAglasLTwarochTESteinerMHuberSHauserMet alEndolysosomal protease susceptibility of amb a 1 as a determinant of allergenicity. J Allergy Clin Immunol. (2018) 141(4):1488–91.e5. 10.1016/j.jaci.2017.10.027
37.
KamathSDScheiblhoferSJohnsonCMMachadoYMcLeanTTakiACet alEffect of structural stability on endolysosomal degradation and T-cell reactivity of major shrimp allergen tropomyosin. Allergy. (2020) 75(11):2909–19. 10.1111/all.14410
38.
da SilvaESAglasLPinheiroCSde Andrade BelitardoEMMSilveiraEFHuberSet alA hybrid of two major Blomia tropicalis allergens as an allergy vaccine candidate. Clin Exp Allergy. (2020) 50(7):835–47. 10.1111/cea.13611
39.
TodaMReeseGGadermaierGSchultenVLauerIEggerMet alProtein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol. (2011) 128(5):1022–30.e7. 10.1016/j.jaci.2011.04.020
40.
AsamCRouliasAParigiani MariaAHaabAWallnerMWolfMet alHarmonization of the genetic code effectively enhances the recombinant production of the major birch pollen allergen bet v 1. Int Arch Allergy Appl Immunol. (2018) 177(2):116–22. 10.1159/000489707
41.
WallnerMHauserMHimlyMZaborskyNMutschlechnerSHarrerAet alReshaping the bet v 1 fold modulates T(H) polarization. J Allergy Clin Immunol. (2011) 127(6):1571–8.e9. 10.1016/j.jaci.2011.01.064
42.
HufnaglKAfifySMBraunNWagnerSWallnerMHauserMet alRetinoic acid-loading of the major birch pollen allergen bet v 1 may improve specific allergen immunotherapy: in silico, in vitro and in vivo data in BALB/c mice. Allergy. (2020) 75(8):2073–7. 10.1111/all.14259
43.
JohnsonLAglasLSohWTGeppertMHoferSHofstatterNet alStructural alterations of antigens at the material interface: an early decision toolbox facilitating safe-by-design nanovaccine development. Int J Mol Sci. (2021) 22(19):10895. 10.3390/ijms221910895
44.
KitzmüllerCWallnerMDeiflSMutschlechnerSWalterskirchenCZlabingerGJet alA hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation. Allergy. (2012) 67(11):1375–82. 10.1111/all.12016
45.
PablosIEichhornSMachadoYBrizaPNeunkirchnerAJahn-SchmidBet alDistinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity. Allergy. (2018) 73(2):431–41. 10.1111/all.13298
46.
GadermaierGHauserMEggerMFerraraRBrizaPSouza SantosKet alSensitization prevalence, antibody cross-reactivity and immunogenic peptide profile of Api g 2, the non-specific lipid transfer protein 1 of celery. PLoS One. (2011) 6(8):e24150. 10.1371/journal.pone.0024150
47.
SchultenVNaglBScalaEBernardiMLMariACiardielloMAet alPru p 3, the nonspecific lipid transfer protein from peach, dominates the immune response to its homolog in hazelnut. Allergy. (2011) 66(8):1005–13. 10.1111/j.1398-9995.2011.02567.x
48.
VejvarEHimlyMBrizaPEichhornSEbnerCHemmerWet alAllergenic relevance of nonspecific lipid transfer proteins 2: identification and characterization of Api g 6 from celery tuber as representative of a novel IgE-binding protein family. Mol Nutr Food Res. (2013) 57(11):2061–70. 10.1002/mnfr.201300085
49.
da SilvaESHuberSAlcantara-NevesNMAsamCSilveiraEFde Andrade BelitardoEMMet alN-terminal peptide deletion influences immunological and structural features of blo t 5. Allergy. (2020) 75(6):1503–7. 10.1111/all.14176
50.
HargadonKM. Murine and human model systems for the study of dendritic cell immunobiology. Int Rev Immunol. (2016) 35(2):85–115. 10.3109/08830185.2014.952413
51.
PatelSHomaeiAEl-SeediHRAkhtarN. Cathepsins: proteases that are vital for survival but can also be fatal. Biomed Pharmacother. (2018) 105:526–32. 10.1016/j.biopha.2018.05.148
52.
BreitenederHKraftD. The history and science of the major birch pollen allergen bet v 1. Biomolecules. (2023) 13(7):1151. 10.3390/biom13071151
53.
SchenkMFGilissenLJWJEsselinkGDSmuldersMJM. Seven different genes encode a diverse mixture of isoforms of bet v 1, the major birch pollen allergen. BMC Genomics. (2006) 7(1):168. 10.1186/1471-2164-7-168
54.
JohnsonLAglasLPunzBDangH-HChristCPointnerLet alMechanistic insights into silica nanoparticle–allergen interactions on antigen presenting cell function in the context of allergic reactions. Nanoscale. (2023) 15(5):2262–75. 10.1039/D2NR05181H
55.
WagnerSRadauerCBublinMHoffmann-SommergruberKKoppTGreiseneggerEKet alNaturally occurring hypoallergenic bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J Allergy Clin Immunol. (2008) 121(1):246–52. 10.1016/j.jaci.2007.08.006
56.
ZaborskyNBrunnerMWallnerMHimlyMKarlTSchwarzenbacherRet alAntigen aggregation decides the fate of the allergic immune response. J Immunol. (2010) 184(2):725–35. 10.4049/jimmunol.0902080
57.
GrutschSFuchsJEAhammerLKamenikASLiedlKRTollingerM. Conformational flexibility differentiates naturally occurring bet v 1 isoforms. Int J Mol Sci. (2017) 18(6):1192. 10.3390/ijms18061192
58.
KamenikASHoferFHandlePHLiedlKR. Dynamics rationalize proteolytic susceptibility of the major birch pollen allergen bet v 1. Front Mol Biosci. (2020) 7:18. 10.3389/fmolb.2020.00018
59.
ConstantSPfeifferCWoodardAPasqualiniTBottomlyK. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med. (1995) 182(5):1591–6. 10.1084/jem.182.5.1591
60.
RouliasAPichlerUHauserMHimlyMHoferHLacknerPet alDifferences in the intrinsic immunogenicity and allergenicity of bet v 1 and related food allergens revealed by site-directed mutagenesis. Allergy. (2014) 69(2):208–15. 10.1111/all.12306
61.
Jahn-SchmidBRadakovicsALuttkopfDScheurerSViethsSEbnerCet alBet v 1142–156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with bet v 1-related food allergens. J Allergy Clin Immunol. (2005) 116(1):213–9. 10.1016/j.jaci.2005.04.019
62.
KitzmüllerCZulehnerNRouliasABrizaPFerreiraFFaéIet alCorrelation of sensitizing capacity and T-cell recognition within the bet v 1 family. J Allergy Clin Immunol. (2015) 136(1):151–8. 10.1016/j.jaci.2014.12.1928
63.
LiccardiGD’AmatoMD’AmatoG. Oleaceae Pollinosis: a review. Int Arch Allergy Appl Immunol. (1996) 111(3):210–7. 10.1159/000237370
64.
StemesederTFreierRWildnerSFuchsJEBrizaPLangRet alCrystal structure of pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family. J Allergy Clin Immunol. (2017) 140(1):277–80. 10.1016/j.jaci.2016.10.035
65.
CardabaBDel PozoVJuradoAGallardoSCorteganoIArrietaIet alOlive pollen allergy: searching for immunodominant T-cell epitopes on the Ole e 1 molecule. Clin Exp Allergy. (1998) 28(4):413–22. 10.1046/j.1365-2222.1998.00190.x
66.
OseroffCSidneyJVitaRTrippleVMcKinneyDMSouthwoodSet alT cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J Immunol. (2012) 189(4):1800–11. 10.4049/jimmunol.1200850
67.
OseroffCSidneyJKotturiMFKollaRAlamRBroideDHet alMolecular determinants of T cell epitope recognition to the common timothy grass allergen. J Immunol. (2010) 185(2):943–55. 10.4049/jimmunol.1000405
68.
ZbîrceaL-EBuzanM-RGrijincuMBabaevEStolzFValentaRet alRelationship between IgE levels specific for ragweed pollen extract, Amb a 1 and cross-reactive allergen molecules. Int J Mol Sci. (2023) 24(4):4040. 10.3390/ijms24044040
69.
PichlerUHauserMWolfMBernardiMLGadermaierGWeissRet alPectate lyase pollen allergens: sensitization profiles and cross-reactivity pattern. PLoS One. (2015) 10(5):e0120038. 10.1371/journal.pone.0120038
70.
Jahn-SchmidBWopfnerNHubingerGAseroREbnerCFerreiraFet alThe T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements. J Allergy Clin Immunol. (2010) 126(5):1068–71.e2. 10.1016/j.jaci.2010.05.038
71.
PhamJOseroffCHinzDSidneyJPaulSGreenbaumJet alSequence conservation predicts T cell reactivity against ragweed allergens. Clin Exp Allergy. (2016) 46(9):1194–205. 10.1111/cea.12772
72.
Jahn-SchmidBHauserMWopfnerNBrizaPBergerUEAseroRet alHumoral and cellular cross-reactivity between Amb a 1, the major ragweed pollen allergen, and its mugwort homolog art v 6. J Immunol. (2012) 188(3):1559–67. 10.4049/jimmunol.1102445
73.
PastorelloEAOrtolaniCFarioliLPravettoniVIspanoMBorgaÅet alAllergenic cross-reactivity among peach, apricot, plum, and cherry in patients with oral allergy syndrome: an in vivo and in vitro study. J Allergy Clin Immunol. (1994) 94(4):699–707. 10.1016/0091-6749(94)90177-5
74.
SalminenTABlomqvistKEdqvistJ. Lipid transfer proteins: classification, nomenclature, structure, and function. Planta. (2016) 244(5):971–97. 10.1007/s00425-016-2585-4
75.
AseroRMistrelloGRoncaroloDde VriesSCGautierMFCiuranaCLet alLipid transfer protein: a pan-allergen in plant-derived foods that is highly resistant to pepsin digestion. Int Arch Allergy Immunol. (2000) 122(1):20–32. 10.1159/000024355
76.
Lindorff-LarsenKWintherJR. Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases. FEBS Lett. (2001) 488(3):145–8. 10.1016/S0014-5793(00)02424-8
77.
PastorelloEAViethsSPravettoniVFarioliLTrambaioliCFortunatoDet alIdentification of hazelnut major allergens in sensitive patients with positive double-blind, placebo-controlled food challenge results. J Allergy Clin Immunol. (2002) 109(3):563–70. 10.1067/mai.2002.121946
78.
SkypalaIJAseroRBarberDCecchiLDiaz PeralesAHoffmann-SommergruberKet alNon-specific lipid-transfer proteins: allergen structure and function, cross-reactivity, sensitization, and epidemiology. Clin Transl Allergy. (2021) 11(3):e12010. 10.1002/clt2.12010
79.
AseroRPravettoniVScalaEVillaltaD. Lipid transfer protein allergy: a review of current controversies. Clin Exp Allergy. (2022) 52(2):222–30. 10.1111/cea.14049
80.
PastorelloEAFarioliLPravettoniVOrtolaniCIspanoMMonzaMet alThe major allergen of peach (Prunus persica) is a lipid transfer protein. J Allergy Clin Immunol. (1999) 103(3):520–6. 10.1016/S0091-6749(99)70480-X
81.
WildnerSGriessnerIStemesederTReglCSohWTStockLGet alBoiling down the cysteine-stabilized LTP fold—loss of structural and immunological integrity of allergenic Art v 3 and Pru p 3 as a consequence of irreversible lanthionine formation. Mol Immunol. (2019) 116:140–50. 10.1016/j.molimm.2019.10.012
82.
TordesillasLCuesta-HerranzJGonzalez-MunozMPaciosLFCompesEGarcia-CarrascoBet alT-cell epitopes of the major peach allergen, Pru p 3: identification and differential T-cell response of peach-allergic and non-allergic subjects. Mol Immunol. (2009) 46(4):722–8. 10.1016/j.molimm.2008.10.018
83.
Ballmer-WeberBKWangorschABuresPHanschmannKMGadermaierGMattssonLet alNew light on an old syndrome: role of Api g 7 in mugwort pollen related celery allergy. J Allergy Clin Immunol. (2024):S0091-6749(24)00502-5. 10.1016/j.jaci.2024.04.030. Online ahead of print.
84.
GadermaierGEggerMGirblTErlerAHarrerAVejvarEet alMolecular characterization of Api g 2, a novel allergenic member of the lipid-transfer protein 1 family from celery stalks. Mol Nutr Food Res. (2011) 55(4):568–77. 10.1002/mnfr.201000443
85.
GadermaierGHarrerAGirblTPalazzoPHimlyMVogelLet alIsoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen. Mol Immunol. (2009) 46(10):1919–24. 10.1016/j.molimm.2009.03.021
86.
CosiVGadermaierG. The role of defensins as pollen and food allergens. Curr Allergy Asthma Rep. (2023) 23(6):277–85. 10.1007/s11882-023-01080-3
87.
HimlyMJahn-SchmidBDedicAKelemenPWopfnerNAltmannFet alArt v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB J. (2003) 17(1):106–8. 10.1096/fj.02-0472fje
88.
LéonardRWopfnerNPabstMStadlmannJPetersenBODuusJØet alA new allergen from ragweed (Ambrosia artemisiifolia) with homology to Art v 1 from mugwort*. J Biol Chem. (2010) 285(35):27192–200. 10.1074/jbc.M110.127118
89.
KumarSKhandpuSRaoDNWahaabSKhannaN. Immunological response to Parthenium hysterophorus in Indian patients with Parthenium sensitive atopic dermatitis. Immunol Invest. (2012) 41(1):75–86. 10.3109/08820139.2011.581731
90.
PablosIEichhornSBrizaPAsamCGartnerUWolfMet alProteomic profiling of the weed feverfew, a neglected pollen allergen source. Sci Rep. (2017) 7(1):6049. 10.1038/s41598-017-06213-z
91.
Jahn-SchmidBFischerGFBohleBFaéIGadermaierGDedicAet alAntigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1∗01. J Allergy Clin Immunol. (2005) 115(2):399–404. 10.1016/j.jaci.2004.10.010
92.
HuangH-JSarzsinszkyEVrtalaS. House dust mite allergy: the importance of house dust mite allergens for diagnosis and immunotherapy. Mol Immunol. (2023) 158:54–67. 10.1016/j.molimm.2023.04.008
93.
OkanoMNaganoTNakadaMMasudaYKinoKYasuedaHet alEpitope analysis of HLA-DR-restricted helper T-cell responses to Der p II, a major allergen molecule of dermatophagoides pteronyssinus. Allergy. (1996) 51(1):29–35. 10.1111/j.1398-9995.1996.tb04546.x
94.
VerhoefAHigginsJAThorpeCJMarshSGHayballJDLambJRet alClonal analysis of the atopic immune response to the group 2 allergen of dermatophagoides spp.: identification of HLA-DR and -DQ restricted T cell epitopes. Int Immunol. (1993) 5(12):1589–97. 10.1093/intimm/5.12.1589
95.
O'HehirREVerhoefAPanagiotopoulouEKeswaniSHayballJDThomasWRet alAnalysis of human T cell responses to the group II allergen of dermatophagoides species: localization of major antigenic sites. J Allergy Clin Immunol. (1993) 92(1 Pt 1):105–13. 10.1016/0091-6749(93)90044-G
96.
WuBElstLVCarlierVJacqueminMGSaint-RemyJ-MR. The dermatophagoides pteronyssinus group 2 allergen contains a universally immunogenic T cell epitope. J Immunol. (2002) 169(5):2430–5. 10.4049/jimmunol.169.5.2430
97.
KrcoCJHardersJChapovalSDavidCS. Immune response of HLA-DQ transgenic mice to house dust mite allergen p2: identification of HLA-DQ restricted minimal epitopes and critical residues. Clin Immunol. (2000) 97(2):154–61. 10.1006/clim.2000.4931
98.
YiFCChuaKYCheongNShekLPLeeBW. Immunoglobulin E reactivity of native blo t 5, a major allergen of Blomia tropicalis. Clin Exp Allergy. (2004) 34(11):1762–7. 10.1111/j.1365-2222.2004.02107.x
99.
StojanovskiBMBreydoLUverskyVNFerreiraGC. Murine erythroid 5-aminolevulinate synthase: truncation of a disordered N-terminal extension is not detrimental for catalysis. Biochim Biophys Acta. (2016) 1864(5):441–52. 10.1016/j.bbapap.2016.02.002
100.
WongKHZhouQPrabhuNFuruhashiKChuaYLGrotenbregGMet alBlomia tropicalis allergen 5 (blo t 5) T-cell epitopes and their ability to suppress the allergic immune response. Immunology. (2017) 152(2):344–55. 10.1111/imm.12772
101.
GaoYFWang deYOngTCTaySLYapKHChewFT. Identification and characterization of a novel allergen from Blomia tropicalis: blo t 21. J Allergy Clin Immunol. (2007) 120(1):105–12. 10.1016/j.jaci.2007.02.032
102.
da Silva ESAsamCLacknerPHoferHWallnerMSilva PinheiroCet alAllergens of Blomia tropicalis: an overview of recombinant molecules. Int Arch Allergy Appl Immunol. (2017) 172(4):203–14. 10.1159/000464325
103.
WaiCYYLeungNYHLeungASYNgaiSMPacharnPYauYSet alComprehending the allergen repertoire of shrimp for precision molecular diagnosis of shrimp allergy. Allergy. (2022) 77(10):3041–51. 10.1111/all.15370
104.
ReschYWeghoferMSeiberlerSHorakFScheiblhoferSLinhartBet alMolecular characterization of der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. Clin Exp Allergy. (2011) 41(10):1468–77. 10.1111/j.1365-2222.2011.03798.x
105.
JeongKYLeeJLeeI-YReeH-IHongC-SYongT-S. Allergenicity of recombinant bla g 7, German cockroach tropomyosin. Allergy. (2003) 58(10):1059–63. 10.1034/j.1398-9995.2003.00167.x
106.
Yadzir ZHMMisnanRAbdullahNBakhtiarFLeecyousBMuradS. Component-resolved diagnosis (CRD): is it worth it? Frequency and differentiation in rhinitis patients with mite reactivity. Iran J Allergy Asthma Immunol. (2014) 13(4):240–6.
107.
JamesJKPikeDHKhanIJNandaV. Structural and dynamic properties of allergen and non-allergen forms of tropomyosin. Structure. (2018) 26(7):997–1006.e5. 10.1016/j.str.2018.05.002
108.
WangSDelgadoJCRavkovEEckelsDDGeorgelasAPavlovIYet alPenaeus monodon tropomyosin induces CD4T-cell proliferation in shrimp-allergic patients. Hum Immunol. (2012) 73(4):426–31. 10.1016/j.humimm.2011.12.019
109.
RenandANewbroughSWambreEDeLongJHRobinsonDKwokWW. Arginine kinase Pen m 2 as an important shrimp allergen recognized by TH2 cells. J Allergy Clin Immunol. (2014) 134(6):1456–9.e7. 10.1016/j.jaci.2014.07.048
110.
FreierRDallEBrandstetterH. Protease recognition sites in Bet v 1a are cryptic, explaining its slow processing relevant to its allergenicity. Sci Rep. (2015) 5:12707. 10.1038/srep12707
111.
PolakDBohleB. Neutrophils-typical atypical antigen presenting cells?Immunol Lett. (2022) 247:52–8. 10.1016/j.imlet.2022.04.007
112.
PolakDElbe-BurgerAKitzmullerCZlabingerGJBohleB. Human neutrophils require short exposure to cytokines and allergen to become functional antigen-presenting cells. Allergy. (2023) 78(1):291–3. 10.1111/all.15460
113.
WosenJEMukhopadhyayDMacaubasCMellinsED. Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front Immunol. (2018) 9:2144. 10.3389/fimmu.2018.02144
114.
SohWTZhangJHollenbergMDVliagoftisHRothenbergMESokolCLet alProtease allergens as initiators-regulators of allergic inflammation. Allergy. (2023) 78(5):1148–68. 10.1111/all.15678
115.
van NielGWubboltsRStoorvogelW. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr Opin Cell Biol. (2008) 20(4):437–44. 10.1016/j.ceb.2008.05.011
Summary
Keywords
endolysosomal degradation assay, antigen processing, allergens, T cell epitopes, mass spectrometry, immunogenicity, proteases
Citation
Öztemiz Topcu E and Gadermaier G (2024) To stay or not to stay intact as an allergen: the endolysosomal degradation assay used as tool to analyze protein immunogenicity and T cell epitopes. Front. Allergy 5:1440360. doi: 10.3389/falgy.2024.1440360
Received
29 May 2024
Accepted
25 June 2024
Published
12 July 2024
Volume
5 - 2024
Edited by
Wai Tuck Soh, Max Planck Institute for Multidisciplinary Sciences, Germany
Reviewed by
Maksymilian Chruszcz, Michigan State University, United States
William Martin, EpiVax, United States
Updates

Check for updates
Copyright
© 2024 Öztemiz Topcu and Gadermaier.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gabriele Gadermaier gabriele.gadermaier@plus.ac.at
ORCID Elif Öztemiz Topcu orcid.org/0000-0001-8002-7921 Gabriele Gadermaier orcid.org/0000-0002-4886-417X
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.